ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 280 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,539,706 | -46.7% | 247,998 | -38.7% | 0.03% | -46.8% |
| Q1 2024 | $12,280,989 | +138.7% | 404,379 | +120.7% | 0.06% | +129.6% |
| Q4 2023 | $5,146,003 | -62.2% | 183,197 | -63.5% | 0.03% | -65.4% |
| Q3 2023 | $13,615,595 | +932.0% | 501,680 | +1270.1% | 0.08% | +1014.3% |
| Q2 2023 | $1,319,310 | 0.0% | 36,617 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $1,319,310 | -6.3% | 36,617 | +2.7% | 0.01% | -12.5% |
| Q4 2022 | $1,408,729 | +16.0% | 35,646 | +17.9% | 0.01% | 0.0% |
| Q3 2022 | $1,214,000 | +75.7% | 30,236 | +70.2% | 0.01% | +166.7% |
| Q1 2022 | $691,000 | -9.3% | 17,761 | -15.9% | 0.00% | -25.0% |
| Q3 2021 | $762,000 | -16.8% | 21,108 | -5.6% | 0.00% | -20.0% |
| Q2 2021 | $916,000 | -29.7% | 22,366 | -25.1% | 0.01% | -28.6% |
| Q1 2021 | $1,303,000 | +16.4% | 29,878 | +33.6% | 0.01% | +16.7% |
| Q4 2020 | $1,119,000 | – | 22,360 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |